Alexander Kula1, Nisha Bansal2. 1. Division of Pediatric Nephrology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. 2. Kidney Research Institute, Division of Nephrology, University of Washington, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: Cardiovascular disease is the leading cause of death in individuals with chronic kidney disease (CKD). The mechanisms connecting CKD and cardiovascular disease are complex, and serum biomarkers can help improve our understanding. Nt-proBNP and troponin have documented success as biomarkers to diagnose and provide mechanistic insights in non-CKD populations. The purpose of this review is to summarize evidence suggesting efficacy and potential for clinical application of Nt-proBNP and troponin in individuals with CKD. RECENT FINDINGS: Our understanding of how Nt-proBNP and Troponin should be interpreted in those with CKD is evolving. Although both biomarkers are in part cleared by the kidney, elevated levels predominantly reflect cardiovascular disease. Both Nt-proBNP and troponin are associated with risk for future cardiovascular events in CKD. Determining CKD-specific cutoffs and using biomarkers to guide therapy remains under active investigation. SUMMARY: Of the many serum biomarkers under investigation, Nt-proBNP and troponin best meet the criteria for effective biomarkers in CKD. Assays are widely available and proven to be accurate in CKD populations. Nt-proBNP and troponin deserve special focus in ongoing research of cardiovascular risk reduction in CKD, especially to identify patients at the highest risk, suggest targetable mechanisms and assess treatment efficacy.
PURPOSE OF REVIEW: Cardiovascular disease is the leading cause of death in individuals with chronic kidney disease (CKD). The mechanisms connecting CKD and cardiovascular disease are complex, and serum biomarkers can help improve our understanding. Nt-proBNP and troponin have documented success as biomarkers to diagnose and provide mechanistic insights in non-CKD populations. The purpose of this review is to summarize evidence suggesting efficacy and potential for clinical application of Nt-proBNP and troponin in individuals with CKD. RECENT FINDINGS: Our understanding of how Nt-proBNP and Troponin should be interpreted in those with CKD is evolving. Although both biomarkers are in part cleared by the kidney, elevated levels predominantly reflect cardiovascular disease. Both Nt-proBNP and troponin are associated with risk for future cardiovascular events in CKD. Determining CKD-specific cutoffs and using biomarkers to guide therapy remains under active investigation. SUMMARY: Of the many serum biomarkers under investigation, Nt-proBNP and troponin best meet the criteria for effective biomarkers in CKD. Assays are widely available and proven to be accurate in CKD populations. Nt-proBNP and troponin deserve special focus in ongoing research of cardiovascular risk reduction in CKD, especially to identify patients at the highest risk, suggest targetable mechanisms and assess treatment efficacy.
Authors: Nisha Bansal; Ronit Katz; Cassianne Robinson-Cohen; Michelle C Odden; Lorien Dalrymple; Michael G Shlipak; Mark J Sarnak; David S Siscovick; Leila Zelnick; Bruce M Psaty; Bryan Kestenbaum; Adolfo Correa; Maryam Afkarian; Bessie Young; Ian H de Boer Journal: JAMA Cardiol Date: 2017-03-01 Impact factor: 14.676
Authors: Peder Langeland Myhre; Muthiah Vaduganathan; Brian Claggett; Milton Packer; Akshay S Desai; Jean L Rouleau; Michael R Zile; Karl Swedberg; Martin Lefkowitz; Victor Shi; John J V McMurray; Scott D Solomon Journal: J Am Coll Cardiol Date: 2019-03-04 Impact factor: 24.094
Authors: Nisha Bansal; Amanda Hyre Anderson; Wei Yang; Robert H Christenson; Christopher R deFilippi; Rajat Deo; Daniel L Dries; Alan S Go; Jiang He; John W Kusek; James P Lash; Dominic Raj; Sylvia Rosas; Myles Wolf; Xiaoming Zhang; Michael G Shlipak; Harold I Feldman Journal: J Am Soc Nephrol Date: 2014-10-02 Impact factor: 10.121
Authors: James L Januzzi; Faiez Zannad; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; João Pedro Ferreira; Naveed Sattar; Subodh Verma; Ola Vedin; Janet Schnee; Tomoko Iwata; Dan Cotton; Milton Packer Journal: J Am Coll Cardiol Date: 2021-09-28 Impact factor: 24.094
Authors: James L Januzzi; Jialin Xu; JingWei Li; Wayne Shaw; Richard Oh; Michael Pfeifer; Javed Butler; Naveed Sattar; Kenneth W Mahaffey; Bruce Neal; Michael K Hansen Journal: J Am Coll Cardiol Date: 2020-11-03 Impact factor: 24.094
Authors: Nathan R Stein; Leila R Zelnick; Amanda H Anderson; Robert H Christenson; Christopher R deFilippi; Rajat Deo; Alan S Go; Jiang He; Bonnie Ky; James P Lash; Stephen L Seliger; Elsayed Z Soliman; Michael G Shlipak; Nisha Bansal Journal: Kidney Int Rep Date: 2020-05-07
Authors: Julio A Lamprea-Montealegre; Leila R Zelnick; Michael G Shlipak; James S Floyd; Amanda H Anderson; Jiang He; Rob Christenson; Stephen L Seliger; Elsayed Z Soliman; Rajat Deo; Bonnie Ky; Harold I Feldman; John W Kusek; Christopher R deFilippi; Myles S Wolf; Tariq Shafi; Alan S Go; Nisha Bansal Journal: J Am Heart Assoc Date: 2019-08-05 Impact factor: 5.501